Quantcast
Last updated on April 18, 2014 at 13:57 EDT

Latest uterine myoma Stories

2008-08-19 03:00:13

Geneva, Switzerland, 19 August 2008 - PregLem SA, a Swiss biopharmaceutical company specialized in reproductive medicine, today announced the start of an international Phase III clinical trial program for PGL4001 (ulipristal) in symptomatic uterine myoma, a common benign solid tumor of the genital tract in women of reproductive age. PGL4001, an orally active, selective progesterone receptor modulator, was shown in a previous Phase II study to be well...